fbpx
    • Multiple Myeloma News
    • Jul 29, 2019

    New Study Helps Researchers Determine Which MGUS Patients Develop Multiple Myeloma

Researchers at the Memorial Sloan Kettering Cancer Center (MSK) published results that found individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. 

The research team hypothesized that changes in serum immune markers over time predicted progression from MGUS to multiple myeloma. They designed the first prospective study with serial blood samples to investigate blood-based immune markers associated with progression from MGUS to multiple myeloma. Currently, based on existing retrospective studies, risk for multiple myeloma is determined when MGUS is diagnosed. This study shows that risk can evolve, and low-risk disease can become high risk and progress to multiple myeloma.

Through a unique collaboration with the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian (NCI-PLCO) cancer screening trial, the prospective study followed 77,469 people, ages 55 to 74 years old, who were all cancer free at the time of enrollment. Using serum collection, researchers identified all subjects who developed myeloma and who had stored preceding samples. They studied the changes in serum immune markers year by year. Study participants donated blood samples annually for 19 years (1992 to 2011). All samples were stored at the National Cancer Institute. Researchers obtained all available serially stored serum samples for all these individuals (3,266 samples in total) and conducted a cross-sectional and longitudinal analyses of serum markers in relation to progression. Researchers also screened over 6,000 people without myeloma to define MGUS cases.

Researchers found that clinical risk categories can change over time prior to multiple myeloma diagnosis. Individuals with low-risk/intermediate-risk MGUS can convert to high-risk MGUS and progress to multiple myeloma within five years; the same result was found in light-chain (characterized by absent M-protein) MGUS. These results support the need for annual blood testing and risk assessment for all individuals with MGUS or light-chain MGUS. Co-leader of the study Dr. C. Ola Landgren said: 

“This study based on prospectively collected samples helps us to better understand the findings of the prior retrospective studies. Previously reported annual risk of progression from MGUS to multiple myeloma of 0.5% to 1% reflected the average risk among all MGUS cases but were not applicable to individual patients. In the current study, we found that the risk of progression is not constant. Our data indicates that individuals with low-risk or intermediate-risk MGUS can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This finding has direct clinical relevance and supports annual blood tests for all individuals diagnosed with MGUS or light-chain MGUS, and, importantly, yearly re-assessment of a patient’s clinical-risk status.”

The Myeloma Crowd Research Initiative is funding work by MSKCC’s Dr. David Chung to create an immune system status assessment. You can learn more and support that research here. 

From original article on Newswise.

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Please enter the correct captcha code to verify that you are human.

MYELOMA CROWD RESEARCH INITIATIVE
$162958 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: